Endometrial Stromal Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumors with YWHAE-NUTM2 fusions and BCOR genetic abnormalities showed morphology characteristic of high-grade endometrial stromal sarcomas.
|
30789359 |
2019 |
Endometrial Stromal Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In an update based on the 2014 WHO classification, low-grade ESS is often associated with gene rearrangement bringing about the JAZF 1-SUZ12 (formerly JAZF1-JJAZ1) fusion gene, whereas high-grade ESS is associated with the YWHAE-NUTM fusion gene.
|
29660202 |
2018 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 40 year old woman was diagnosed with metastatic YWHAE-FAM22 translocated endometrial stromal sarcoma.
|
29357824 |
2018 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endometrial stromal sarcoma (ESS) characterized by YWHAE-NUTM2A/B genetic fusion is a recently recognized entity that is classified as a high-grade (HG) ESS in the 2014 World Health Organization Classification.
|
27171540 |
2017 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Strong diffuse nuclear BCOR staining (defined as >95% of tumor cells) was seen in the round cell component of all 20 (100%) classic YWHAE-NUTM2 high-grade endometrial stromal sarcomas and the 3 unusual high-grade endometrial stromal sarcomas which prompted FISH studies confirming YWHAE rearrangement in 2 tumors.
|
28621321 |
2017 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Not all HG tumors showed a YWHAE-NUTM chimeric transcript and as many as six LGESS showed no hitherto known ESS-related fusions.
|
27219024 |
2016 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We applied an NGS-based fusion transcript detection assay (Archer FusionPlex Sarcoma Panel) that targets YWHAE and JAZF1 fusions in a series of low-grade ESSs (n = 11) and high-grade ESSs (n = 5) that were previously confirmed to harbour genetic rearrangements by fluorescence in-situ hybridization (FISH) and/or reverse transcription polymerase chain reaction (RT-PCR) analyses.
|
26990025 |
2016 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were no clinical features able to recognize YWHAE-NUTM2 ESS.
|
25244606 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Endometrial stromal sarcomas (ESSs) frequently harbor genetic fusions, including JAZF1-SUZ12 and equivalent fusions in low-grade ESS (LGESS) and YWHAE-NUTM2 in high-grade ESS (HGESS).
|
25288234 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The ESTs that show higher grade atypia but lack nuclear pleomorphism include YWHAE-FAM22 ESS.Here we report an unusual case of ESTs.
|
24750188 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Endometrial stromal tumors: the new WHO classification.
|
25299308 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The chimeric transcripts described in endometrial stromal sarcomas (ESS) are JAZF1/SUZ12, YWHAE/FAM22, ZC3H7/BCOR, MBTD1/CXorf67, and recombinations of PHF1 with JAZF1, EPC1, and MEAF6.
|
24530230 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene expression profiles of seven ESS (including three with YWHAE and two with JAZF1 rearrangements) and four UES without specific chromosomal aberrations indicated clustering of tumors with MBTD1-CXorf67 fusion together with low-grade JAZF1-associated ESS.
|
23959973 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Collectively, these findings suggest that abnormality in the loci of YWHAE, FAM22A and FAM22B, which are known to be associated with oncogenesis of endometrial stromal sarcoma, may contribute to the development of uterine angiosarcoma.
|
24125656 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement.
|
24186140 |
2014 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The reverse transcription-polymerase chain reaction assay optimized for formalin-fixed and paraffin-embedded samples detected YWHAE-FAM22 fusion transcripts in all 6 YWHAE-FAM22 endometrial stromal sarcomas and none of the 24 non-YWHAE-FAM22 uterine sarcomas.
|
23159154 |
2013 |
Endometrial Stromal Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined YWHAE rearrangements by FISH break-apart and RT-PCR in a series of 27 undifferentiated uterine stromal sarcoma without JAZF1 rearrangements.
|
23599159 |
2013 |
Endometrial Stromal Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumors with YWHAE-FAM22 rearrangements constitute a distinct group of ESS, which is associated with high-grade morphology and aggressive clinical behavior compared to JAZF1 ESS.
|
22456610 |
2012 |
Endometrial Stromal Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YWHAE-FAM22 fusion gene knockdowns were performed with shRNAs and siRNAs targeting various FAM22A exons in an t(10;17)-bearing ESS cell line (ESS1): Fusion protein expression was inhibited, with corresponding reduction in cell growth and migration.
|
22223660 |
2012 |
Endometrial Stromal Sarcoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma.
|
22223660 |
2012 |
Endometrial Stromal Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemically, the high-grade round cell component of all 12 YWHAE-FAM22 ESS demonstrated diffuse (≥70%) moderate to strong nuclear cyclin D1 staining, and this diffuse positivity was not seen in 34 ESSs with JAZF1 and equivalent genetic rearrangements or in 21 low-grade ESS with no demonstrable genetic rearrangements.
|
22982899 |
2012 |